NCT04349267

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.

You may be eligible to participate in the study if you meet the following criteria:

Inclusion Criteria:

Participants must have histologic confirmation of advanced (metastatic, recurrent, and/or unresectable) squamous cell carcinoma of the head and neck (SCCHN), nonsmall cell lung cancer (NSCLC), or renal cell cancer (RCC) with measurable disease per RECIST 1.1
Participants expected to have received standard of care therapies including an available PD-(L)1 inhibitor
Eastern cooperative oncology group performance status of 0 or 1
Women of childbearing potential must agree to follow methods of contraception

Exclusion Criteria:

Participants with active, known or suspected autoimmune disease
Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications
Uncontrolled or significant cardiovascular disease
History of or with active interstitial lung disease or pulmonary fibrosis
Prior participation in anti-natural killer cell receptor (anti-NKG2A) clinical study
History of allergy or hypersensitivity to study drug components

Other protocol-defined inclusion/exclusion criteria apply

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

Contact the study center to learn if this study is a good match for you.

Contition

Advanced Solid Tumor

Age (in years)

18+

Phase

Phase 1/Phase 2

Participants needed

308

Est. Completion Date

May 30, 2025

Treatment type

Interventional

Sponsor

Bristol-Myers Squibb

ClinicalTrials.gov identifier

NCT04349267

Study number

CA047004